Abstract: Disclosed is a hair care composition comprising: a cationic surfactant system; a high melting point fatty compound; a fatty ester of benzoic acid; a non-volatile hydrocarbon oil; and an aqueous carrier. The compositions of the present invention provide conditioning benefits, especially dry conditioning benefits, while providing improved clean feel.

Abstract: Disclosed is a method of preparing a product composition comprising steps of: Preparing a mixture composition comprising a surfactant and a high melting point fatty compound; Separately preparing an aqueous base composition comprising a surfactant, a high melting point fatty compound, and an aqueous carrier, and wherein the aqueous base composition is substantially free of detersive surfactant; Mixing the mixture composition and the aqueous base composition to form a discrete particle of the mixture composition dispersed in the aqueous base composition. Alternatively, the method comprises steps of preparing a discrete particle of the mixture composition; and mixing it with the aqueous composition. The methods of the present invention provide a product composition with at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; and improved deposition of benefit agents when the base composition further comprises such benefit agents.

Abstract: Disclosed is a product composition comprising: a discrete particle of a mixture composition, wherein the mixture composition comprises a surfactant and a high melting point fatty compound; and an aqueous base composition comprising an aqueous carrier, and water soluble polymer, wherein the base composition is substantially free of a detersive surfactant selected from anionic surfactants, zwitterionic surfactant, amphoteric surfactant, and combinations thereof. The product composition of the present invention provides at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; improved deposition of benefit agents when the base composition further comprises such benefit agents; and improved visual/aesthetic appearance.

Abstract: Aqueous surfactant compositions containing one or more alpha-sulfo fatty acid disalt (A) of general formula (I), R1CH(SO3M1)COOM2??(I), in which the radical R1 is a linear or branched alkyl or alkenyl radical having 6 to 18 carbon atoms and the radicals M1 and M2, independently of one another, are selected from the group consisting of H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine, one or more alkanolamide (B) selected from the group of compounds of general formula (IIa), (IIb) and (IIc), R13—CO—NR14R15??(IIa) R13—CO—NR14R16??(IIb) R13—CO—NR14R17??(IIc) wherein the radical R13 in compounds (IIa) is a linear or branched alkyl radical having 6 to 18 carbon atoms and the radicals R14 and R15, independently of each other, are a linear or branched hydroxyalkyl group having 1 to 4 carbon atoms; wherein the radical R13 in compounds (IIb) is a linear or branched alkyl radical having 6 to 18 carbon atoms, the radical R14 is a linear or branched hydroxyalkyl group having 1 to 4 carbon a

Abstract: The disclosure relates to compositions and methods for removing cosmetic films and makeup compositions from keratinous fibers. Compositions comprise at least one low-viscosity, low-volatility silicone. Methods comprise applying the compositions to keratinous fibers.

Abstract: The present invention features cosmetic compositions and a method for pigmentations that creates realistic and long-wear freckles on a user's skin.

Abstract: An emulsifier is comprised of core-corona type microparticles that an emulsification capability thereof is not affected by the crosslinking level and an oil-in-water emulsified cosmetic emulsified by the afore-mentioned emulsifier.

Abstract: Disclosed are hair care compositions, such as conditioners, containing a metathesized unsaturated polyol ester; and a gel matrix phase comprising one or more high melting point fatty compounds, a cationic surfactant system an aqueous carrier. The oligomers provide beneficial hair benefits. Also disclosed are methods of using the hair care compositions.

Abstract: The invention relates to methods for preparing plant extracts having elastase inhibitory activity from a Myrsine africana plant and topical skin care compositions comprising such plant extracts. The invention further relates to plant extracts and compositions for use in cosmetic methods of inhibiting elastase activity in skin. The invention is also directed to the use of plant extracts from the plant Myrsine africana in methods of prevention or treatment of skin aging in a subject and methods of using the plant extracts from Myrsine africana.

Abstract: The present invention relates generally to methods of use and compositions useful for moisturizing skin and/or lightening or whitening skin. The composition includes a combination of Angelica acutiloba root extract and a Salicornia herbacea extract.

Abstract: The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.

Abstract: The present invention relates generally to topical antiviral compositions, delivery systems, and methods of using the same.

Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Abstract: The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin.

Abstract: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.

Abstract: Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective ?1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective ?1 adrenergic receptor blocker and class I antiarrhythmic agent.

Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: Provided herein are methods and compositions for the targeted delivery to myometrial tissue of one or more agents capable of regulating contractility of myometrial tissue, wherein the one or more agents are contained or encapsulated within a polymeric delivery vehicle conjugated with one or more molecules that recognizes and/or is capable of binding, directly or indirectly, to the oxytocin receptor.

Abstract: The present invention relates to extracellular vesicles (EVs) comprising a binding protein which may be used for delivery of protein-drug conjugates comprising the binding protein and a small molecule agent, typically a small molecule drug. The present invention also relates to methods for producing such EVs as well as pharmaceutical compositions and medical uses of such EVs.

Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.

Abstract: Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.

Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.

Abstract: The present invention relates to an improved powdered extrudate based on polyvinyl alcohol (PVA), which can be used for pharmaceutical products, and that, due to its improved properties, can be better filled into capsules and the capsules show stable immediate drug release kinetic without problem of particle aggregation. Furthermore, this invention refers to pharmaceutical capsule composition comprising extruded polyvinyl alcohol as carrier matrix and can improve the solubility of API within immediate release kinetic. Moreover, the capsule show also benefit than tablet regarding to the material cost, because just PVA and API, no additional excipients are needed for capsule.

Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Abstract: A nanoparticle suitable for delivery of an active agent across the blood-brain barrier is provided. As such, the nanoparticle can target brain tissue so that the active agent can be delivered across the blood-brain barrier to the target brain tissue. The nanoparticle includes a core that includes a core material such as a polymer or inorganic material as well as an active agent; and a shell comprising a membrane derived from a brain metastatic cancer cell, wherein the brain metastatic cancer cell facilitates transport of the nanoparticle across a blood-brain barrier. Also disclosed are methods of forming the nanoparticle and methods of using the nanoparticle.

Abstract: Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

Abstract: A method for forming encapsulated gold nanoparticles mixes mangiferin into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts is permitted, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin. The gold salts can consist of AuCl4, or can consist of radioactive gold salts. A cancer therapy method injects a solution of mangiferin encapsulated gold nanoparticles directly into a solid tumor. A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles is provided. The mangiferin encapsulated gold nanoparticles can have core sizes of ˜5-20 nm and total sizes of ˜20-120 nm.

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.

Abstract: The present disclosure provides methods, compositions, devices and systems for dermal and transdermal administration of treprostinil or salts thereof, and optionally an additional therapeutic agent. Treprostinil and salts thereof can be dermally or transdermally administered to treat any medical conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Abstract: This invention provides an effective method and a composition for treating neurodegenerative diseases and conditions of the central and peripheral nervous system by stimulating neurogenesis by the use isoxylitones or an isomer, acid analog, a salt or a solvate, thereof.

Abstract: The invention pertains to a composition comprising Curcuminoids and Garcinol for hepatoprotection. Specifically, the invention discloses a composition comprising 95% Curcuminoids and 20% Garcinol for the therapeutic management of Non-alcoholic fatty liver disease (NAFLD) and associated conditions like steatosis, Non-alcoholic steatoheapatitis (NASH), fibrosis and cirrhosis of the liver.

Abstract: A method for treating depression in patients with depression and bipolar disorder who have not responded to antidepressants and to avoid dose dumping upon ingestion of alcohol. The present invention also relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.

Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.

Abstract: The invention provides a method for preventing and/or treating Alzheimer's disease in a subject in need of such treatment, comprising administrating to said subject an effective amount of a curcumin derivative, TML-6, and optionally a pharmaceutically acceptable carrier or excipient.

Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of eczema. The compositions may include propionic acid and/or non-steroidal esters of propionic acid. The compositions may further include a corticosteroid, immunomodulator, antibiotic, antibody, colloidal oatmeal, conditioned media prepared by bacterial fermentation, short chain fatty acids, picolinic acid, or emollient. The method of treatment may include analysis of the skin microbiome.

Abstract: The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Abstract: Methods of administering methyldopa to a subject in a fasting state to increase bioavailability of the methyldopa.

Abstract: An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

Abstract: It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.

Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.

Abstract: The cis-isomer and trans-isomers of the plant-derived compound gnetin H are shown have anticancer properties, anti-inflammatory properties, and low toxicity. Therapeutic and prophylactic compositions that contain cis-gnetin H, trans-gnetin H, an derivatives thereof, as well as methods of making and using said compositions, are provided. cis-gnetin H and/or trans-gnetin H can be used in purified form or as a plant extract.

Abstract: The present invention is related to a method of treating idiopathic pulmonary fibrosis comprising administering to a subject in need thereof an effective amount of a composition containing a compound that binds FK506 binding protein 4.

Abstract: The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products.

Abstract: Methods of reducing the risk of cancer after surgery, e.g., of cancer recurrence, by administering COX-1 selective inhibitors prior to surgery or biopsy. Alternatively or in addition, other anti-platelet agents and/or TGF-? inhibition and/or IL-6 inhibition and/or inhibitors of the PD-1/PD-L1 axis, as well as combinations thereof.

Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.